Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets.   Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion pounds, reflecting continued growth across disease areas, with strong performance in HIV, respiratory/immunology, and oncology. HIV drug revenues increased 14% to 1.6 billion Pounds. General Medicines sales rose marginally by 1% to 2.6 billion pounds. Trelegy (asthma drug) sales reached 0.6 billion Pounds, up 33%. The company ...